BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24586944)

  • 1. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.
    Di Martino MT; Gullà A; Gallo Cantafio ME; Altomare E; Amodio N; Leone E; Morelli E; Lio SG; Caracciolo D; Rossi M; Frandsen NM; Tagliaferri P; Tassone P
    PLoS One; 2014; 9(2):e89659. PubMed ID: 24586944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
    Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
    Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.
    Morelli E; Biamonte L; Federico C; Amodio N; Di Martino MT; Gallo Cantafio ME; Manzoni M; Scionti F; Samur MK; Gullà A; Stamato MA; Pitari MR; Caracciolo D; Sesti S; Frandsen NM; Rossi M; Neri A; Fulciniti M; Munshi NC; Tagliaferri P; Tassone P
    Blood; 2018 Sep; 132(10):1050-1063. PubMed ID: 29997223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
    Di Martino MT; Gullà A; Cantafio ME; Lionetti M; Leone E; Amodio N; Guzzi PH; Foresta U; Conforti F; Cannataro M; Neri A; Giordano A; Tagliaferri P; Tassone P
    Oncotarget; 2013 Feb; 4(2):242-55. PubMed ID: 23479461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo.
    Torres A; Kozak J; Korolczuk A; Rycak D; Wdowiak P; Maciejewski R; Torres K
    Oncotarget; 2016 Nov; 7(45):73651-73663. PubMed ID: 27655663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
    Monoe Y; Jingushi K; Kawase A; Hirono T; Hirose R; Nakatsuji Y; Kitae K; Ueda Y; Hase H; Abe Y; Adachi J; Tomonaga T; Tsujikawa K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
    Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P
    J Hematol Oncol; 2023 Jun; 16(1):68. PubMed ID: 37365583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.
    Gallo Cantafio ME; Nielsen BS; Mignogna C; Arbitrio M; Botta C; Frandsen NM; Rolfo C; Tagliaferri P; Tassone P; Di Martino MT
    Mol Ther Nucleic Acids; 2016 Jun; 5(6):. PubMed ID: 27327137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach.
    Nedaeinia R; Sharifi M; Avan A; Kazemi M; Rafiee L; Ghayour-Mobarhan M; Salehi R
    Cancer Gene Ther; 2016 Aug; 23(8):246-53. PubMed ID: 27364574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.
    Gu C; Jing X; Holman C; Sompallae R; Zhan F; Tricot G; Yang Y; Janz S
    BMC Cancer; 2018 Nov; 18(1):1152. PubMed ID: 30463534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-361-3p is a potent therapeutic target for oral squamous cell carcinoma.
    Ogawa H; Nakashiro KI; Tokuzen N; Kuribayashi N; Goda H; Uchida D
    Cancer Sci; 2020 May; 111(5):1645-1651. PubMed ID: 32086979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression.
    Murphy BL; Obad S; Bihannic L; Ayrault O; Zindy F; Kauppinen S; Roussel MF
    Cancer Res; 2013 Dec; 73(23):7068-78. PubMed ID: 24145352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth.
    Yan LX; Wu QN; Zhang Y; Li YY; Liao DZ; Hou JH; Fu J; Zeng MS; Yun JP; Wu QL; Zeng YX; Shao JY
    Breast Cancer Res; 2011 Jan; 13(1):R2. PubMed ID: 21219636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activity of miR-92a-Locked Nucleic Acid (LNA)-Inhibitor against endometrial cancer.
    Torres A; Kozak J; Korolczuk A; Wdowiak P; Domańska-Glonek E; Maciejewski R; Torres K
    BMC Cancer; 2016 Oct; 16(1):822. PubMed ID: 27782822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
    Di Martino MT; Campani V; Misso G; Gallo Cantafio ME; Gullà A; Foresta U; Guzzi PH; Castellano M; Grimaldi A; Gigantino V; Franco R; Lusa S; Cannataro M; Tagliaferri P; De Rosa G; Tassone P; Caraglia M
    PLoS One; 2014; 9(2):e90005. PubMed ID: 24587182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
    Cosco D; Cilurzo F; Maiuolo J; Federico C; Di Martino MT; Cristiano MC; Tassone P; Fresta M; Paolino D
    Sci Rep; 2015 Dec; 5():17579. PubMed ID: 26620594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LNA Inhibitor in microRNA miR-23b as a Potential Anti-proliferative Option in Human Hepatocellular Carcinoma.
    Najafi Z; Sharifi M; Javadi G
    J Gastrointest Cancer; 2020 Mar; 51(1):109-115. PubMed ID: 30815771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma.
    Li Z; Liu L; Du C; Yu Z; Yang Y; Xu J; Wei X; Zhan F; Lai Y; Qiu L; Hao M
    Cancer Gene Ther; 2020 Dec; 27(12):869-877. PubMed ID: 31988477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.